Vera Therapeutics VERA
$25.45 −$1.30 (-4.86%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $24.88 -2.24%
Open$26.37
Prev close$26.75
Day range$25.16 – $27.15
Volume1.37M
Market cap$1.84B
P/E (TTM)–
Dividend yield–
VERA Stock News
Headlines matching Vera Therapeutics or the VERA ticker, most recent first.
- Is NVIDIA (NVDA.US) facing renewed resistance as its stock price hits new highs? Amid surging demand for both GPUs and Vera CPUs, a director has cashed out $300 million in a major sell-off.
- NVIDIA's stock hits a new high but faces resistance again? As demand for GPUs and Vera CPUs surges on two fronts, a Director has cashed out $300 million. Positive
- Wedbush Maintains Vera Therapeutics(VERA.US) With Hold Rating, Maintains Target Price $34
- A Quick Look at Today's Ratings for Vera Therapeutics(VERA.US), With a Forecast Between $34 to $90
- TD Cowen Maintains Vera Therapeutics(VERA.US) With Buy Rating, Maintains Target Price $78
- Takeda Pharmaceutical: Regarding the U.S. Food and Drug Administration (FDA) approval of MIMRYLO (rusfertide), which has the potential to usher in a paradigm shift in the treatment of polycythemia vera. Positive
- Takeda Pharmaceutical: Takeda Receives U.S. FDA Approval of MIMRYLO (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera Positive
- J.P. Morgan Maintains Vera Therapeutics(VERA.US) With Buy Rating, Cuts Target Price to $76 Negative
- Wells Fargo Maintains Vera Therapeutics(VERA.US) With Buy Rating, Maintains Target Price $70
- HC Wainwright & Co. Maintains Buy on Vera Therapeutics, Lowers Price Target to $90
- H.C. Wainwright Maintains Vera Therapeutics(VERA.US) With Buy Rating, Cuts Target Price to $90 Negative
- A Quick Look at Today's Ratings for Vera Therapeutics(VERA.US), With a Forecast Between $34 to $100
- Wedbush Maintains Vera Therapeutics(VERA.US) With Hold Rating, Cuts Target Price to $43 Negative
- LifeSci Capital Maintains Vera Therapeutics(VERA.US) With Buy Rating, Maintains Target Price $90
- Evercore Maintains Vera Therapeutics(VERA.US) With Buy Rating, Maintains Target Price $91
No comments yet — be the first to weigh in on VERA.
Sign in to join the discussion.